292 References
Lewis G, Peake M, Aultman R, Gyldmark M, Morlotti L, Creeden J, de la Orden M.
Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of
advanced non-small-cell lung cancer in the United Kingdom. J. Int. Med. Res.
2010; 38(1): 9–21.
Lin DY. Proportional means regression for censored medical costs. Biometrics 2000;
56(3): 775–8.
Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-
up data. Biometrics 1997; 53(2): 419–34.
Liu L, Strawderman RL, Cowen ME, Shih YC. A exible two-part random effects
model for correlated medical costs. J. Health Econ. 2010; 29(1): 110–23.
Machin D, Campbell MJ, Tan SB, Tan SH. Sample Size Tables for Clinical Studies, 3rd
edn. Oxford: John Wiley, 2009